تطوير وتقييم صيغ صيدلانية مقترحة لحثيرات معدلة التحرر حاوية على السيليكوكسيب لاستخدامها في تحضير مضغوطات ذات تحرر مديد

[1] N. B. Demina, “Modern trends in development of the technology of matrix drug dosage forms with modified release (a review),” Pharmaceutical Chemistry Journal, vol. 50, no. 7, pp. 44–50, 2016, doi: 10.30906/0023-1134-2016-50-7-44-50.

[2] World Health Organization (WHO), “Musculoskeletal conditions.” [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions.

[3] J. M. Hootman, C. G. Helmick, K. E. Barbour, K. A. Theis, and M. A. Boring, “Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015–2040,” Arthritis & Rheumatology, vol. 68, no. 7, pp. 1582–1587, 2016, doi: 10.1002/art.39692.

[4] I. N. Samartsev, S. A. Zhivolupov, and R. Z. Nazhmudinov, “Identification of non-steroidal anti-inflammatory drugs as a necessity basis of effectiveness and risk correlation conception,” Zhurnal Nevrologii i Psikhiatrii im. S. S. Korsakova, vol. 119, no. 12, pp. 124–131, 2019, doi: 10.17116/jnevro2019119121124.

[5] F. Meng, R. Ferreira, and F. Zhang, “Effect of surfactant level on properties of celecoxib amorphous solid dispersions,” Journal of Drug Delivery Science and Technology, vol. 49, pp. 301–307, 2019, doi: 10.1016/j.jddst.2018.11.026.

[6] Pfizer Inc., “Celecoxib compositions,” U.S. Patent RE44048. [Online]. Available: http://labeling.pfizer.com/ShowLabeling.aspx?id=793.

[7] European Patent Office, “Celecoxib compositions,” EP 1049467 B1.

[8] M. V. Grigor’yeva, “Polymer systems with controlled release of bioactive compounds,” Biotechnologia Acta, vol. 4, no. 2, 2011.

[9] P. Salve, S. Aherrao, and N. Bali, “Development and evaluation of sustained release dosage form using hydrophilic and hydrophobic materials,” Research Journal of Pharmacy and Technology, vol. 9, no. 5, pp. 481–489, 2016, doi: 10.5958/0974-360X.2016.00089.5.

[10] X. Qi et al., “Floating tablets for controlled release of ofloxacin via compression coating of hydroxypropyl cellulose combined with effervescent agent,” International Journal of Pharmaceutics, vol. 489, no. 1–2, pp. 210–217, 2015, doi: 10.1016/j.ijpharm.2015.05.007.

[11] K. A. A. Abdulhameed and N. A. Salih, “Controlled release of cefixime using sodium carboxymethyl cellulose polymer,” Research Journal of Pharmacy and Technology, vol. 12, no. 9, pp. 4073–4079, 2019, doi: 10.5958/0974-360X.2019.00701.7.

[12] F. Zhang, F. Meng, Z. Y. Wang, and W. Na, “Interpolymer complexation between copovidone and carbopol and its effect on drug release from matrix tablets,” Drug Development and Industrial Pharmacy, vol. 43, no. 2, pp. 190–203, 2017, doi: 10.1080/03639045.2016.1230625.

[13] S. K. Paulson et al., “Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 2, pp. 638–645, 2001.

[14] United States Pharmacopeial Convention, USP 43–NF 38, 2022. [Online]. Available: https://www.uspnf.com/notices/usp-43-nf-38-online-table-contents-admissions.

[15] P. Thapa, A. R. Lee, D. H. Choi, and S. H. Jeong, “Effects of moisture content and compression pressure of various deforming granules on the physical properties of tablets,” Powder Technology, vol. 310, pp. 92–102, 2017, doi: 10.1016/j.powtec.2017.01.021.

[16] L. Fitriani, R. Abdillah, and E. S. Ben, “Formulation of metformin HCl floating tablet using HPC, HPMC K100M, and the combinations,” Jurnal Sains Farmasi & Klinis, vol. 4, no. 1, pp. 79–82, 2017, doi: 10.29208/jsfk.2017.4.1.201.

[17] S. Suslina and A. Alkhodri, “Preparation, evaluation and development celecoxib prolonged release (PR) tablets by using cellulose polyacrylic acid-based polymers,” Research Journal of Pharmacy and Technology, vol. 15, no. 4, pp. 1727–1731, 2022, doi: 10.52711/0974-360X.2022.00289.